vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $94.9M, roughly 2.0× DYNAVAX TECHNOLOGIES CORP). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs 28.4%, a 19.6% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs -21.9%). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs -15.4%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
DVAX vs RILY — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $188.3M |
| Net Profit | $26.9M | $90.3M |
| Gross Margin | — | 79.5% |
| Operating Margin | 22.4% | 32.3% |
| Net Margin | 28.4% | 47.9% |
| Revenue YoY | 17.7% | -21.9% |
| Net Profit YoY | 53.0% | 1710.8% |
| EPS (diluted) | $0.21 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $188.3M | ||
| Q3 25 | $94.9M | $215.3M | ||
| Q2 25 | $95.4M | $188.2M | ||
| Q1 25 | $68.2M | $197.2M | ||
| Q4 24 | $72.0M | $241.0M | ||
| Q3 24 | $80.6M | $225.5M | ||
| Q2 24 | $73.8M | $256.0M | ||
| Q1 24 | $50.8M | $263.4M |
| Q4 25 | — | $90.3M | ||
| Q3 25 | $26.9M | $91.1M | ||
| Q2 25 | $18.7M | $139.5M | ||
| Q1 25 | $-96.1M | $-10.0M | ||
| Q4 24 | $7.0M | $-5.6M | ||
| Q3 24 | $17.6M | $-284.4M | ||
| Q2 24 | $11.4M | $-433.6M | ||
| Q1 24 | $-8.7M | $-49.2M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
| Q4 25 | — | 32.3% | ||
| Q3 25 | 22.4% | 30.4% | ||
| Q2 25 | 15.1% | 5.7% | ||
| Q1 25 | -34.7% | -31.2% | ||
| Q4 24 | -2.3% | -69.2% | ||
| Q3 24 | 12.5% | -36.4% | ||
| Q2 24 | 7.0% | -90.8% | ||
| Q1 24 | -35.0% | -6.1% |
| Q4 25 | — | 47.9% | ||
| Q3 25 | 28.4% | 42.3% | ||
| Q2 25 | 19.6% | 74.1% | ||
| Q1 25 | -141.0% | -5.1% | ||
| Q4 24 | 9.8% | -2.3% | ||
| Q3 24 | 21.8% | -126.1% | ||
| Q2 24 | 15.4% | -169.4% | ||
| Q1 24 | -17.2% | -18.7% |
| Q4 25 | — | $2.78 | ||
| Q3 25 | $0.21 | $2.91 | ||
| Q2 25 | $0.14 | $4.50 | ||
| Q1 25 | $-0.77 | $-0.39 | ||
| Q4 24 | $0.07 | $-0.01 | ||
| Q3 24 | $0.12 | $-9.39 | ||
| Q2 24 | $0.08 | $-14.35 | ||
| Q1 24 | $-0.07 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $534.1M | $-171.5M |
| Total Assets | $946.5M | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $226.6M | ||
| Q3 25 | $160.2M | $184.2M | ||
| Q2 25 | $99.1M | $267.4M | ||
| Q1 25 | $51.7M | $138.3M | ||
| Q4 24 | $95.9M | $146.9M | ||
| Q3 24 | $119.3M | $159.2M | ||
| Q2 24 | $112.5M | $236.9M | ||
| Q1 24 | $132.0M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-171.5M | ||
| Q3 25 | $534.1M | $-260.5M | ||
| Q2 25 | $494.2M | $-351.7M | ||
| Q1 25 | $530.9M | $-496.8M | ||
| Q4 24 | $596.8M | $-488.2M | ||
| Q3 24 | $681.4M | $-497.6M | ||
| Q2 24 | $642.8M | $-218.3M | ||
| Q1 24 | $618.5M | $228.4M |
| Q4 25 | — | $1.7B | ||
| Q3 25 | $946.5M | $1.7B | ||
| Q2 25 | $918.4M | $1.5B | ||
| Q1 25 | $945.9M | $1.5B | ||
| Q4 24 | $986.3M | $1.8B | ||
| Q3 24 | $1.1B | $2.2B | ||
| Q2 24 | $1.0B | $3.2B | ||
| Q1 24 | $986.6M | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $26.2M |
| Free Cash FlowOCF − Capex | $32.6M | — |
| FCF MarginFCF / Revenue | 34.4% | — |
| Capex IntensityCapex / Revenue | 1.3% | — |
| Cash ConversionOCF / Net Profit | 1.26× | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $26.2M | ||
| Q3 25 | $33.8M | $-60.6M | ||
| Q2 25 | $23.4M | $-25.6M | ||
| Q1 25 | $-19.6M | $184.0K | ||
| Q4 24 | $53.0M | $-2.7M | ||
| Q3 24 | $19.5M | $19.5M | ||
| Q2 24 | $10.7M | $111.5M | ||
| Q1 24 | $-16.7M | $135.4M |
| Q4 25 | — | — | ||
| Q3 25 | $32.6M | — | ||
| Q2 25 | $22.0M | — | ||
| Q1 25 | $-23.6M | — | ||
| Q4 24 | $49.5M | — | ||
| Q3 24 | $18.1M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $-17.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | 34.4% | — | ||
| Q2 25 | 23.0% | — | ||
| Q1 25 | -34.6% | — | ||
| Q4 24 | 68.8% | — | ||
| Q3 24 | 22.5% | — | ||
| Q2 24 | 13.5% | — | ||
| Q1 24 | -34.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.5% | — |
| Q4 25 | — | 0.29× | ||
| Q3 25 | 1.26× | -0.66× | ||
| Q2 25 | 1.25× | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
